Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy

Seminars in Radiation Oncology
Nan Bi, Luhua Wang

Abstract

Treatment of inoperable, locally advanced non-small cell lung cancer (LA-NSCLC) is challenging and requires a multidisciplinary approach considering both local therapy and systemic therapy. Based on the results from several phase III studies and 2 meta-analyses, the use of concomitant chemoradiation therapy (ChRT) could significantly improve overall survival and is considered the standard of care in LA-NSCLC with good performance status. Currently, no evidence has shown a significant survival benefit of third-generation regimens applied in combination with ChRT compared with second-generation regimens. For regimens concomitant with radiation therapy, full-dose chemotherapy (such as cisplatin and etoposide or cisplatin and vinblastine) might be preferred. Additional full-dose consolidation paclitaxel-carboplatin is recommended when patients receive weekly paclitaxel-carboplatin ChRT. Effective novel chemotherapy agents or targeted therapies are required to further improve the outcome of patients with LA-NSCLC. In addition, personalized medicine concomitant with radiation therapy is a promising approach. However, little evidence exists concerning the effectiveness of this novel approach.

References

Jan 1, 1978·International Journal of Radiation Oncology, Biology, Physics·G G SteelM J Peckham
Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Dec 30, 1998·International Journal of Radiation Oncology, Biology, Physics·B JeremicS Milisavljevic
Mar 10, 2001·International Journal of Radiation Oncology, Biology, Physics·S TyldesleyW J Mackillop
Jul 23, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E SchildUNKNOWN North Central Cancer Treatment Group
Aug 5, 2003·The Oncologist·Giorgio V Scagliotti, Andrew T Turrisi
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J M GroenN H Mulder
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
May 29, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Saban Cakir, Ibrahim Egehan
Sep 15, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Petr ZatloukalLadislav Pecen
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chandra P BelaniWalter J Curran
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FournelUNKNOWN Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rudolf M HuberUNKNOWN Bronchial Carcinoma Therapy Group
Nov 7, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·José BelderbosUNKNOWN EORTC LCG and RT Group
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everett E VokesUNKNOWN Cancer and Leukemia Group B
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A William Blackstock, Ramaswamy Govindan
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Sep 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nicholas W ChoongEverett E Vokes
Jun 3, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Oscar ArrietaJaime de la Garza
Dec 3, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Daniel MorgenszternRamaswamy Govindan
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne AupérinJean-Pierre Pignon
Jun 24, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A JatoiA A Adjei
Aug 6, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Neal ReadyUNKNOWN Cancer, Leukemia Group B, Chicago, IL
Sep 11, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Isamu OkamotoNobuyuki Yamamoto
Nov 9, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yaping XuGuoqin Qiu
Mar 19, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shirish M GadgeelAndrew Turrisi
Mar 19, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nagio TakigawaMitsune Tanimoto
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George R BlumenscheinRitsuko Komaki
Sep 10, 2011·Journal of the National Cancer Institute·Walter J CurranJames D Cox
Mar 16, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Luhua WangXiangru Zhang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.